Amanda Manoogian, PharmD, BCOP, Clinical Pharmacy Coordinator Specialty Pharmacy - Clinical Services (Partners Healthcare)

The recent development of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, as well as alpelisib (Piqray), a phosphoinositide 3-kinase (PI3K) inhibitor, has changed the way patients with HR-positive MBC are treated.